Michael Kelly
Vorstandsvorsitzender bei NERVGEN PHARMA CORP.
Vermögen: 944 897 $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Richard Lowenthal | M | 58 |
ARS Subsidiary, Inc.
 ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 9 Jahre |
| Sarina Tanimoto | M | 55 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 9 Jahre |
| Robert Bell | M | - |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 9 Jahre |
| Brian Dorsey | M | 55 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 6 Jahre |
| Jonathan Leff | M | 55 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 6 Jahre |
| Phillip Schneider | M | 68 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 5 Jahre |
| Rajeev Dadoo | M | 54 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 3 Jahre |
| Pratik Shah | M | 54 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 8 Jahre |
| Justin Chakma | M | 35 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 5 Jahre |
| Glenn Ives | M | 62 | 3 Jahre | |
| Peter Kolchinsky | M | 47 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 3 Jahre |
| Harold Punnett | M | 67 | 7 Jahre | |
| Brenton Saunders | M | 56 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 3 Jahre |
| Saqib Islam | M | 54 | 2 Jahre | |
| Krista McKerracher | F | - | 3 Jahre | |
| Adam Rogers | M | - | 2 Jahre | |
| Eric Karas | M | 52 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 2 Jahre |
| Alexander Fitzpatrick | M | 57 | 2 Jahre | |
| Kathleen Scott | F | 55 |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | 2 Jahre |
| Peter Thompson | M | 64 | 2 Jahre | |
| Brian Bayley | M | 71 | 6 Jahre | |
| Randall Kaye | M | 61 | 4 Jahre | |
| John Thompson | M | 57 | 2 Jahre | |
| John Ruffolo | M | - | 1 Jahre | |
| Laura Shawver | M | 66 | 2 Jahre | |
| Bill Adams | M | 62 | 4 Jahre | |
| Daniel Relovsky | M | - | 2 Jahre | |
| Daniel Mikol | M | - | 3 Jahre | |
| Phillip Lieberman | M | - |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | - |
| Guy Ludbrook | M | - |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | - |
| Estelle Simons | F | - |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | - |
| Motohiro Ebisawa | M | - |
ARS Subsidiary, Inc.
ARS Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA. | - |
| Huitt Tracey | M | 64 | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Craig R. Smith | M | 77 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 11 Jahre |
| William Radvak | M | 61 | 7 Jahre | |
| Andrew R. Jordan | M | - |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 12 Jahre |
| Dean Mitchell | M | 68 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 1 Jahre |
| Asher M. Rubin | M | 53 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Donald W. Fallon | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
| Eunan Maguire | M | - |
Jazz Pharmaceuticals Commercial Corp.
 Jazz Pharmaceuticals Commercial Corp. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals Commercial Corp. provides pharmaceutical services. It engages in identifying, developing, and commercializing products in the areas of CNS, women's health, and urology. The company was founded in 2005 and is headquartered in Philadelphia, PA. | 7 Jahre |
| Barry Michael Fox | M | - |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Matthew Ruth | M | - |
Jazz Pharmaceuticals Commercial Corp.
Jazz Pharmaceuticals Commercial Corp. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals Commercial Corp. provides pharmaceutical services. It engages in identifying, developing, and commercializing products in the areas of CNS, women's health, and urology. The company was founded in 2005 and is headquartered in Philadelphia, PA. | 5 Jahre |
| Francesca M. Cook | F | 58 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
| Barbara Slusher | M | 59 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Charles Reinhart | M | 63 |
Covis Pharmaceuticals, Inc.
 Covis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Covis Pharmaceuticals, Inc. specializes and distributes pharmaceutical products. It is a specialty pharmaceutical distributor dedicated to improving the lives of people with life-threatening conditions and chronic illnesses. The company was founded on November 2, 2011 and is headquartered in Chesterbrook, PA. | 1 Jahre |
| David P. Wright | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
| David Domzalski | M | 58 |
Jazz Pharmaceuticals Commercial Corp.
Jazz Pharmaceuticals Commercial Corp. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals Commercial Corp. provides pharmaceutical services. It engages in identifying, developing, and commercializing products in the areas of CNS, women's health, and urology. The company was founded in 2005 and is headquartered in Philadelphia, PA. | 1 Jahre |
| John P. Brennan | M | 66 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Alexander Sapir | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
| Matthew Wiley | M | 52 |
Jazz Pharmaceuticals Commercial Corp.
Jazz Pharmaceuticals Commercial Corp. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals Commercial Corp. provides pharmaceutical services. It engages in identifying, developing, and commercializing products in the areas of CNS, women's health, and urology. The company was founded in 2005 and is headquartered in Philadelphia, PA. | 5 Jahre |
| Zhong Zhao | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 6 Jahre |
| Nancy J. Linck | M | 82 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Joseph R. Chinnici | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| David C. U'Prichard | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Solomon H. Snyder | M | - |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Walter M. Lovenberg | M | 89 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Ronald M. Nordmann | M | 82 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Wilmer Leigh Thompson | M | 85 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Joseph Klein | M | 62 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 7 Jahre |
| Elizabeth M. Greetham | F | 74 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Thomas C. Seoh | M | 66 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Peter David Suzdak | M | 65 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 7 Jahre |
| George Bunting | M | 82 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Andrew J. Jeanneret | M | 59 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
| William Spengler | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 1 Jahre |
| William C. Vincek | M | 76 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Margaret M. Contessa | F | - |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Fady Boctor | M | 47 |
Emergent Devices, Inc.
 Emergent Devices, Inc. Pharmaceuticals: MajorHealth Technology Part of Emergent BioSolutions, Inc., Emergent Devices, Inc. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Plymouth Meeting, PA. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 56 | 82,35% |
| Kanada | 12 | 17,65% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Kelly
- Persönliches Netzwerk
